Skip to main content
MedPathMedPath Home
Clinical Trials/NCT02641184
NCT02641184
Unknown
N/A

A Multicenter Prospective Observational Study to Evaluate the Novel Risk Factors and Clinical Outcomes of Acute Myocardial Infarction (AMI)

Zhejiang Provincial People's Hospital1 site in 1 country3,000 target enrollmentDecember 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCoronary Artery DiseasePercutaneous Coronary InterventionAcute Myocardial Infarction

Overview

Phase
N/A
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Zhejiang Provincial People's Hospital
Enrollment
3000
Locations
1
Primary Endpoint
Major adverse cardiovascular events (MACE)
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The aim of this study is to investigate the potential novel risk factors for acute myocardial infarction. Predictors of poor outcomes will be also evaluated.

Registry
clinicaltrials.gov
Start Date
December 2015
End Date
December 2017
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Xiao Ye, MD

Doctor

Zhejiang Provincial People's Hospital

Eligibility Criteria

Inclusion Criteria

  • •Less than 12 hours after the onset of myocardial infarction symptoms
  • •Myocardial necrosis, as evidenced by increased Creatine Kinase Isoenzyme (CK-MB) or troponin levels

Exclusion Criteria

  • •Age under 18 years-old

Outcomes

Primary Outcomes

Major adverse cardiovascular events (MACE)

Time Frame: maximum 5 years

Composite of angina pectoris, reinfarction, unplanned rehospitalization, stent thrombosis, incidence of cardiac death in the duration of follow-up

Secondary Outcomes

  • New-onset diabetes(the duration of follow-up, maximum 5 years)
  • Length of hospital stay(in the phase of hospital stay, maximum 30 days)

Study Sites (1)

Loading locations...

Similar Trials

Withdrawn
N/A
Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)Metabolic Syndrome
NCT02069717Daewoong Pharmaceutical Co. LTD.
Not Yet Recruiting
N/A
Multicenter Prospective Cohort Study of Risk Factors for Gallbladder CancerGallbladder DiseasesHealthy
NCT03762837Tongji Hospital100,000
Completed
N/A
Observational Prospective Study OPTIMA II - Follow-upMajor Adverse Cardiovascular and Cerebrovascular Events (MACCE)
NCT02099565AstraZeneca572
Completed
N/A
Epidemiologic Study to Evaluate the Proportion of Cardiovascular Disease Risk Factors in Korean Hypertensive PatientsHypertension
NCT01362283GlaxoSmithKline3,109
Recruiting
N/A
Evaluation of HEArt invoLvement in Patients With FABRY DiseaseRare DiseasesFabry DiseaseFabry Disease, Cardiac VariantHypertrophic Cardiomyopathy
NCT03362164Wuerzburg University Hospital650